Top Markets
#1 Pleasing Gold Pleasing Gold +738.04%
#2 Islamic Coin Islamic Coin +154.23%
#3 PulseChain PulseChain +56.20%
#4 BOOK OF MEME BOOK OF MEME +40.59%
#5 DogBull DogBull +37.66%
#6 Collect on Fanable Collect on Fanable +26.22%
#7 Nockchain Nockchain +19.04%
#8 Neiro Neiro +18.83%
#9 rsERG rsERG +17.72%
#10 PondCoin PondCoin +17.19%
Coin of the day
Pleasing Gold Pleasing Gold
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Decibel Therapeutics, Inc. Decibel Therapeutics, Inc.

Decibel Therapeutics, Inc.

DBTX
Rang în acțiuni #26962
Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm... Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1. Gene Therapies for Congenital, Monogenic Hearing Loss: These programs aim to re-establish functional cellular activity within the cochlea, thereby counteracting hearing deficiencies stemming from single gene mutations. 2. Gene Therapies for Hair Cell Regeneration: This pipeline focuses on replenishing lost hair cells in the inner ear to alleviate acquired hearing and balance conditions. 3. Otoprotection Therapeutic: Currently in clinical development, this therapeutic is designed to safeguard cancer patients from hearing loss induced by cisplatin chemotherapy. A flagship gene therapy candidate, DB-OTO, is being developed to restore auditory function in individuals suffering from profound hearing loss linked to mutations in the otoferlin gene. The company is also advancing several other programs, including DB-ATO and AAV.201, gene therapies intended to regenerate lost vestibular hair cells and thus re-establish balance in patients with bilateral vestibulopathy. DB-020 is undergoing Phase 1b clinical trials for the prevention of hearing loss caused by cisplatin. Further gene therapies in development include AAV.103 for individuals with a gap junction beta-2 (GJB2) deficiency, AAV.104 for those with a stereocilin (STRC) deficiency, and a cochlear hair cell regeneration program that employs AAV-based gene therapy to convert supporting cells into functional outer hair cells using cell-selective reprogramming factors. Decibel Therapeutics maintains a strategic alliance with Regeneron Pharmaceuticals, Inc., specifically for co-developing gene therapies addressing monogenic forms of inherited hearing loss. Established in 2013 and initially known as Hearing Inc., the company rebranded as Decibel Therapeutics, Inc. in April 2014. Its operations are headquartered in Boston, Massachusetts.
Preț acțiune
$4.91
Ultima sincronizare: 2023-10-04
Capitalizare de piață
$36.12M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Decibel Therapeutics, Inc. (DBTX)

Categorie

Healthcare
Raport P/E pentru Decibel Therapeutics, Inc. (DBTX)
Raport P/E la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Decibel Therapeutics, Inc., raportul P/E actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/E de 0.
Istoricul raportului P/E pentru Decibel Therapeutics, Inc. din 2026 până în 2026
Raportul P/E la sfârșitul fiecărui an
An Raport P/E Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raportul P/E pentru companii similare sau concurenți
Companie P/E Ratio Diferență P/E Ratio Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cum interpretezi un P/E ratio?

Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.

Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.

Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.